公开(公告)号：WO2022256865A1

公开(公告)日：2022-12-15

申请号：PCT/AU2022/050561

申请日：2022-06-08

Applicant: SIDHU, Kuldip ,  CUNNINGHAM, Corey

Inventor： SIDHU, Kuldip ,  CUNNINGHAM, Corey

IPC: A61K35/28 ,  A61K9/00 ,  A61P21/00 ,  A61P25/00 ,  A61P27/00 ,  C12N5/0775

Abstract: The present invention relates to human mesenchymal stem cell lines produced in serum-free and predominantly xenogeneic-free conditions. In particular, the invention relates to exosomes derived from such human mesenchymal stem cell lines and their use in the treatment of spinal cord injury.

公开(公告)号：WO2022256300A1

公开(公告)日：2022-12-08

申请号：PCT/US2022/031551

申请日：2022-05-31

Applicant: VERGE ANALYTICS, INC.

Inventor： ROSEN, Mark, D. ,  LIANG, Weiling ,  GALEMMO, JR., Robert, A.

IPC: C07D487/04 ,  A61P3/00 ,  A61P21/00 ,  A61P25/00 ,  A61P35/00 ,  A61K31/4162

Abstract: The present disclosure provides compounds of formula (I) that are inhibitors of PlKfyve kinase and are therefore useful for the treatment of neurological diseases treatable by inhibition of PlKfyve kinases. Also provided are pharmaceutical compositions containing such compounds, and methods of treatment of neurological diseases using such compounds.

公开(公告)号：WO2022256298A1

公开(公告)日：2022-12-08

申请号：PCT/US2022/031548

申请日：2022-05-31

Applicant: VERGE ANALYTICS, INC.

Inventor： ROSEN, Mark D. ,  LIANG, Weiling ,  GALEMMO, JR., Robert A.

IPC: C07D487/04 ,  A61K31/519 ,  A61P25/00 ,  A61P25/02 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28

Abstract: The present invention relates to compounds of formula (I) that are inhibitors of PlKfyve kinase and are therefore useful for the treatment of e.g. neurological diseases, such as e.g. amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, Huntington's disease, ADHD, schizophrenia, depression, or bipolar disorder. An exemplary compound is e.g. 4-[7-[3-(m-tolyl)pyrazol-l-yl]-2-(3- pyridyl)imidazo[l,2-a] pyrimidin-5-yl] morpholine (compound 3) Data on the PlKfyve kinase inhibition are provided:

公开(公告)号：WO2022256215A1

公开(公告)日：2022-12-08

申请号：PCT/US2022/030996

申请日：2022-05-26

Applicant: TEVA PHARMACEUTICALS INTERNATIONAL GMBH ,  TEVA PHARMACEUTICALS USA, INC.

Inventor： LUTHRA, Parven Kumar ,  MUTHUSAMY, Anantha Rajmohan ,  SOMASUNDARAM, Meenakshi Sundaram

IPC: C07D209/52 ,  A61P25/00 ,  A61P43/00

Abstract: The present disclosure encompasses a solid state form of Centanafadine HCl, processes for preparation thereof, and pharmaceutical compositions thereof.

公开(公告)号：WO2022254027A1

公开(公告)日：2022-12-08

申请号：PCT/EP2022/065235

申请日：2022-06-03

Applicant: REWIND THERAPEUTICS NV

Inventor： PERICOLLE, Vincent ,  VANHERCK, Jean-Christophe ,  MARCHAND, Arnaud Didier Marie ,  DUVEY, Guillaume Albert Jacques ,  PINTO, Rui Miguel Garcia Costa

IPC: C07D207/36 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D409/06 ,  C07D417/04 ,  A61K31/40 ,  A61K31/4439 ,  A61P25/00

Abstract: The present invention relates to a compound of formula (I), or a tautomer, a stereoisomer, a hydrate, a solvate, a polymorph, a prodrug, an isotope, or a co-crystal thereof, or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined in the description and claims. The present invention also relates to a pharmaceutical composition comprising a compound according to the invention, and a pharmaceutical acceptable carrier. The present invention also relates to the present compounds for use as a medicine and/or as diagnostics. The present invention also relates to the present compounds for use in the prevention and/or treatment of GPR17 mediated disorders, such as for example a disorder or syndrome selected from a myelination disorder and a disorder or syndrome associated with brain tissue damage.

公开(公告)号：WO2022251654A1

公开(公告)日：2022-12-01

申请号：PCT/US2022/031371

申请日：2022-05-27

Applicant: WEST VIRGINIA UNIVERSITY BOARD OF GOVERNORS ON BEHALF OF WEST VIRGINIA UNIVERSITY

Inventor： GELDENHUYS, Werner ,  HAZLEHURST, Lori ,  KAULAGARI, Sridhar Reddy

IPC: A61K31/426 ,  A61P25/00 ,  A61P29/00

Abstract: Stroke or ischemia/reperfusion injury may be treated with a compound of formula (I), a compound of formula (II), pharmaceutically acceptable salts thereof, mixtures thereof, enantiomers thereof, or racemates thereof: wherein X is a chalcogen, e.g., O, S, or Se; NH; NR5, where R5 is a C1 to C8 alkyl group or a C1 to C8 acyl group; BR6, where R6 is a halogen, e.g., fluorine, bromine, or iodine, H, lower alkyl, or lower alkoxy; or Si(R7)2, where R7 is a C1 to C8 alkyl group or a C1 to C8 acyl group; and R1, R2, R3, and R4 are independently hydrogen, a C1 to C8 alkyl group, hydroxy, alkoxy, aryloxy, acyloxy, a thiol group, a thioalkyl group, a thioacyl group, a sulfonamide group, an amino group, a mono- or dialkylamino group, an acylamino group, or a halogen.

公开(公告)号：WO2022251533A1

公开(公告)日：2022-12-01

申请号：PCT/US2022/031186

申请日：2022-05-26

Applicant: PROTEGO BIOPHARMA, INC. ,  THE SCRIPPS RESEARCH INSTITUTE

Inventor： LABAUDINIERE, Richard F. ,  TAIT, Bradley Dean ,  PETRASSI, Hank Michael James ,  KELLY, Jeffery W. ,  WISEMAN, R. Luke ,  LEE, Kyunga ,  GUERRERO, Adrian Marco

IPC: C07D231/40 ,  C07D233/88 ,  C07D401/12 ,  C07D403/12 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4439 ,  A61P3/00 ,  A61P9/00 ,  A61P19/00 ,  A61P25/00

Abstract: Provided herein are compounds that activate IRE1/XBP1s, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for treating a subject having a disease or disorder that may be ameliorated by increasing IRE1/XBP1s activity.

公开(公告)号：WO2022251048A1

公开(公告)日：2022-12-01

申请号：PCT/US2022/030167

申请日：2022-05-20

Applicant: ELI LILLY AND COMPANY

Inventor： SIMS, John Randall II

IPC: A61K39/395 ,  C07K16/18 ,  A61P25/00 ,  A61K39/00

Abstract: The present disclosure is directed to treatment or prevention of a disease characterized by deposition of Aβ in the brain using anti-Aβ antibodies. The diseases that can be treated or prevented include, e.g., Alzheimer's disease, Down's syndrome, and cerebral amyloid angiopathy. The invention, in some aspects, is related to doses and dosing regimens useful for such treatments. The invention is also related to, in some aspects, human subjects who are responsive to treatment or prevention of a disease characterized by Aβ in the brain using anti-Aβ antibodies. The invention is also related to patients who have one or more alleles of APOE e4.

公开(公告)号：WO2022250499A1

公开(公告)日：2022-12-01

申请号：PCT/KR2022/007581

申请日：2022-05-27

Applicant: SK BIOPHARMACEUTICALS CO., LTD.

Inventor： PENDSE, Pravada ,  BOMMANA, Murali M ,  NOH, Regina H. ,  PEGAN, Augustin ,  WEBB, Travis John ,  MAXWELL, Jejuan

IPC: A61K9/08 ,  A61K9/10 ,  A61K47/10 ,  A61K47/02 ,  A61K47/36 ,  A61K47/38 ,  A61K9/00 ,  A61K31/41 ,  A61P25/00

Abstract: The present disclosure relates to an aqueous formulation comprising as an active ingredient a carbamate compound of Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, poloxamer, and an aqueous carrier, wherein the aqueous formulation is in the form of a suspension formulation.

公开(公告)号：WO2022249942A1

公开(公告)日：2022-12-01

申请号：PCT/JP2022/020635

申请日：2022-05-18

Applicant: 国立大学法人岩手大学

Inventor： 山下　哲郎 ,  尾▲崎▼　拓

IPC: A61K31/131 ,  A61K31/145 ,  A61P25/00 ,  A61P27/02 ,  A61P27/06

Abstract: 本発明の課題は、網膜神経節細胞や網膜視細胞に例示される網膜の神経細胞の保護剤を提供することである。その解決手段としての本発明の網膜の神経細胞の保護剤は、一般式：Ｒ１－（ＣＨ２）ｍ－ＳＲ２で表される化合物またはその薬学的に許容される塩を有効成分とする（式中、Ｒ１は－ＮＲ３Ｒ４または炭素数１～６のアルキル基を示す。Ｒ２は水素原子または－Ｓ－（ＣＨ２）ｎ－ＮＲ５Ｒ６を示す。Ｒ３～Ｒ６は同一または異なって水素原子またはアセチル基を示す。ｍとｎは同一または異なって２～４の整数を示す。）。